# EDGAR Filing Document

**Accession Number:** 0001455767
**File Stem:** 0000899243-23-004578
**Filing Date:** 2023-2
**Character Count:** 9915
**Document Hash:** 27142f22872fb2acd127e761a5eb6e2b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-004578.hdr.sgml**: 20230210

**ACCESSION NUMBER**: 0000899243-23-004578

**CONFORMED SUBMISSION TYPE**: 5

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230210

**DATE AS OF CHANGE**: 20230210

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Erdtmann Rainer M
- **CENTRAL INDEX KEY:** 0001455767

**FILING VALUES:**
- **FORM TYPE:** 5
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40335
- **FILM NUMBER:** 23612226

**MAIL ADDRESS:**
- **STREET 1:** 1073 ARLINGTON BLVD.
- **CITY:** EL CERRITO
- **STATE:** CA
- **ZIP:** 94530
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biomea Fusion, Inc.
- **CENTRAL INDEX KEY:** 0001840439
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 900 MIDDLEFIELD ROAD
- **STREET 2:** 4TH FLOOR
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** (650) 980-9099

**MAIL ADDRESS:**
- **STREET 1:** 900 MIDDLEFIELD ROAD
- **STREET 2:** 4TH FLOOR
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Erdtmann Rainer M<br><sub>(Last) (First) (Middle)</sub><br>C/O BIOMEA FUSION, INC.<br>900 MIDDLEFIELD ROAD, 4TH FLOOR<br><sub>(Street)</sub><br>REDWOOD CITY, CA 94063<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President & COO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Biomea Fusion, Inc. [ BMEA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2022-07-01 |  | G |  | 100000 | D | $0.00 | 849127<sup>(1)</sup> | D<sup>(2)</sup> |  |
| Common Stock | 2022-08-16 |  | G |  | 17100 | D | $0.00 | 832027 | D<sup>(2)</sup> |  |
| Common Stock | 2022-08-19 |  | G |  | 16000 | D | $0.00 | 816027 | D<sup>(2)</sup> |  |
| Common Stock | 2022-12-28 |  | G |  | 4000 | D | $0.00 | 812027 | D<sup>(2)</sup> |  |
| Common Stock | 2022-12-28 |  | G |  | 4000 | A | $0.00 | 6400 | I | By daughter |
| Common Stock | 2022-12-28 |  | G |  | 4000 | D | $0.00 | 808027 | D<sup>(2)</sup> |  |
| Common Stock | 2022-12-28 |  | G |  | 4000 | A | $0.00 | 7000 | I | By daughter |
| Common Stock | 2022-12-28 |  | G |  | 4000 | D | $0.00 | 804027 | D<sup>(2)</sup> |  |
| Common Stock | 2022-12-28 |  | G |  | 4000 | A | $0.00 | 7000 | I | By son |
| Common Stock | 2022-12-28 |  | G |  | 70000 | D | $0.00 | 734027 | D<sup>(2)</sup> |  |
| Common Stock |  |  |  |  |  |  |  | 174614<sup>(3)</sup> | I | See Footnote<sup>(4)</sup> |
| Common Stock |  |  |  |  |  |  |  | 1134989<sup>(5)</sup> | I | See Footnote<sup>(6)</sup> |
| Common Stock |  |  |  |  |  |  |  | 228470 | I | See Footnote<sup>(7)</sup> |
| Common Stock |  |  |  |  |  |  |  | 252320 | I | See Footnote<sup>(8)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Includes 873,068 shares received prior to the gift in a distribution-in-kind, without consideration, from Biomea Health, LLC made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

(2) Includes 76,059 shares held directly by the Reporting Person and the remaining shares are held directly by the Reporting Person through a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

(3) Includes 174,614 shares received in a prior distribution-in-kind, without consideration, from Biomea Health, LLC made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Exchange Act.

(4) The shares are held by a trust having an independent trustee ("Trust 1").  The Reporting Person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

(5) Includes 1,134,989 shares received in a prior distribution-in-kind, without consideration, from Biomea Health, LLC made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Exchange Act.

(6) The shares are held by a trust having an independent trustee ("Trust 2").  The Reporting Person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

(7) The shares are held directly by Point Sur Investors Fund I, LP ("Point Sur LP"). The General Partner of Point Sur LP is Point Sur Investors LLC. Rainer M Erdtmann and Thomas Butler are the managing members of Point Sur Investors, LLC and as such have voting and dispositive power over the securities held by Point Sur LP. The Reporting Person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

(8) The shares are held directly by Point Sur Investors, LLC. Rainer M Erdtmann and Thomas Butler are the managing members of Point Sur Investors, LLC and as such have voting and dispositive power over the securities held by Point Sur Investors, LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

**Signature:** /s/ Franco Valle as Attorney-in-fact for Rainer M. Erdtmann  
**Date:** 2023-02-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**